Get started
Markets Canada Stocks Non-Energy Minerals Other Metals/Minerals

BIOVAXYS TECHNOLOGY CORP BIOV

BIOVCSE
BIOV
BIOVAXYS TECHNOLOGY CORPCSE
See more on advanced chartSee more on advanced chart
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
News Ideas Financials Technicals

BIOV chart

Ideas

BIOV -- FDA approval for COVID-19 clinical trials
BIOV
, 1DLong
BIOV: BIOV -- FDA approval for COVID-19 clinical trials

Biotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study: FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical...

BIOV.C -- Gap fill / insiders buying
BIOV
, 1D
BIOV: BIOV.C -- Gap fill / insiders buying

BIOV.C may have found a bottom at ~ .19 after filling the gap with insiders recently buying at over .30. Approaching oversold area on the Daily chart.

BIOV.C -- COVID-19 and Cancer Treatment / Vaccine Development
BIOV
, 1DLong
BIOV: BIOV.C -- COVID-19 and Cancer Treatment / Vaccine Development
Updated 

BIOV is breaking out after a series of very promising press releases concerning their COVID-19 and cancer treatment/vaccine solutions. Still under the radar and will likely see lots of upside from here.

Technicals

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins}
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Non-Energy Minerals
Industry: Other Metals/Minerals
BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Vancouver, Canada.

News flow

More news